Olema Pharmaceuticals (OLMA) announced a new clinical trial collaboration and supply agreement with Pfizer (PFE) in metastatic breast cancer. The companies will evaluate in a Phase 1b/2 study the safety and combinability of palazestrant plus atirmociclib, Pfizer’s investigational, highly selective-CDK4 inhibitor, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. Under the terms of the agreement, Pfizer will supply atirmociclib for use in the Phase 1b/2 study and Olema will lead the conduct of the study. All clinical data and inventions relating to the combined use of atirmociclib and palazestrant resulting from the study will be jointly owned, with Olema maintaining full global commercial and marketing rights to palazestrant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Strategic Advancements and Market Potential in Oncology Drive Buy Rating
- Promising Efficacy and Strategic Partnerships Drive Buy Rating for Olema Pharmaceuticals
- Citi ups Olema target, adds ‘upside catalyst watch’
- Olema Pharmaceuticals Advances Breast Cancer Therapies
- Olema Pharmaceuticals: Promising Advancements in ER+ Breast Cancer Treatment and Strategic Positioning Justify Buy Rating